alosetron sold brand name lotronex among others antagonist used management severe diarrheapredominant irritable bowel syndrome ibs females patented approved medical use currently marketed prometheus laboratories inc san diego alosetron withdrawn market owing occurrence serious lifethreatening gastrointestinal adverse effects reintroduced availability use restricted alosetron indicated women severe diarrheapredominant irritable bowel syndrome ibsd severe ibsd includes diarrhea following phase iii trial approval published industryfunded randomized placebocontrolled trial pct authors found mg alosetron taken orally twice daily weeks associated ci improvement relief abdominal pain discomfort associated diarrheapredominant prescription alosetron currently approved us fda medical officers review dated november noted patients considered investigators fit diarrheapredominant subtype baseline stool consistency values neither loose fdas gastrointestinal drugs advisory committee referred drugs efficacy modest highlighting placebo brought relief primary outcome measure lotronexs prescribing information brochure states alosetron initiated patients constipation contraindications history chronic severe constipation sequelae constipation intestinal obstruction stricture toxic megacolon gastrointestinal perforation andor adhesions ischemic colitis impaired intestinal circulation thrombophlebitis hypercoagulable state crohns disease ulcerative colitis diverticulitis severe hepatic impairment concomitant use fluvoxamine also alosetron withdrawn following association alosetron serious lifethreatening gastrointestinal adverse effects cumulative incidence ischaemic colitis serious complications arising constipation obstruction perforation impaction toxic megacolon secondary colonic ischaemia death review performed fda medical officer john senior indicated patients experienced phase iii trial reported constipation occurred patients alosetron placebo groups respectively cited important reason patients dropping alosetron antagonist action receptors enteric nervous system gastrointestinal tract antagonist like ondansetron classified approved antiemetic since stimulation receptors positively correlated gastrointestinal motility alosetrons antagonism slows movement fecal matter large intestine increasing extent water absorbed decreasing moisture volume remaining waste alosetron originally approved us food drug administration fda february sevenmonth time initial approval us food drug administration fda reviewers found alosetron improved symptoms shipment pharmacies started march july health professional filed report fda death woman suffered mesenteric ischemia report identified alosetron primary suspect alosetron withdrawn market voluntarily glaxowellcome november owing occurrence serious lifethreatening gastrointestinal adverse effects including deaths additional bowel fda said reports cases ischemic colitis cases severe constipation ten patients underwent surgeries others examined hospitals released without surgery november pharmacists filled prescriptions severe adverse events continued reported final total instances ischaemic colitis severe constipation admissions hospital patient advocacy groups notably lotronex action group international foundation functional gastrointestinal disorders iffgd lobbied drugs return public citizen health research group another patient advocacy group opposed june fda announced approval supplemental new drug application snda allows restricted marketing lotronex alosetron hydrochloride treat women severe diarrheapredominant irritable bowel syndrome strict prescribing guidelines initially introduced relaxed slightly enabling electronic prescriptions among benefits known whether alosetron filed registration eu gsk sold lotronex californian corporation prometheus late since generic versions alosetron available us sold number different companies including actavis pharma company prometheus laboratories sebela pharmaceuticals inc editor renowned medical journal lancet richard horton criticized fdas handling alosetron unusually sharp horton argued treatment nonfatal condition justify use drug potentially lethal side effects fda revoked approval alosetron sooner postmarketing surveillance revealed many patients suffered constipation necessitating surgical intervention ischaemic colitis asserted fda officials improperly motivated maintain reinstate approval alosetron extent fdas center drug evaluation research funded user fees paid pharmaceutical manufacturers reinstatement alosetron negotiated confidential meetings representatives glaxosmithkline article published british medical journal bmj noted allowing marketing alosetron drug poses serious significant public health concern according terms fda failed others argued approval process lotronex example regulatory httpsenwikipediaorgwikialosetron